Pre-admission use of sodium glucose transporter-2 inhibitor (SGLT-2i) may significantly improves Covid-19 outcomes in patients with diabetes: A systematic review, meta-analysis, and meta-regression
Pooled result · Covid-19 mortalityResult — go to the resultOdds ratio 0.69 95% CI 0.56–0.87Authors' conclusion
This study suggests that SGLT-2i as glucose lowering treatment in patients with diabetes has a positive effect on Covid-19 outcomes, therefore can be considered as an antidiabetic drug of choice, especially during the Covid-19 pandemic. Short Title: SGLT-2i in diabetes and Covid-19.
Study context
- Population
- Diabetic patients with Covid-19; 4 databases searched until October 24th, 202217 studies
- Comparison
- Pre-admission SGLT-2i use vs no use
- Outcome
- Covid-19 mortality
Methodological detailsrandom-effect models
- Random-effect models
Pooled result
As reported in the abstract
Odds ratio
0.69
95% CI 0.56–0.87
P = 0.001
SGLT-2ivs No SGLT-2i
OR 0.69 (95% CI 0.56–0.87); P = 0.001
Further pooled results
| Outcome | OR (95% CI) | P value | |
|---|---|---|---|
| Covid-19 severityI2 = 13 % | 0.88 (0.80–0.97) | P = 0.008 | |
| 0.512Odds ratio (log scale) |
Meta-regression: effect on mortality by patient factors
- Not significantly affected by age
- P = 0.2335
- Not significantly affected by sex
- P = 0.2742
- Not significantly affected by hypertension
- P = 0.2165
- Not significantly affected by HF
- P = 0.1616
- Not significantly affected by HbA1c levels
- P = 0.4924
- Not significantly affected by metformin use
- P = 0.6617
- Not significantly affected by duration of diabetes
- P = 0.7233
- Not significantly affected by BMI
- P = 0.1797
Original publication
Pre-admission use of sodium glucose transporter-2 inhibitor (SGLT-2i) may significantly improves Covid-19 outcomes in patients with diabetes: A systematic review, meta-analysis, and meta-regression. Diabetes Res Clin Pract. Published 9 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →